The Technical Scientific Commission (CTS) of AIFA has approved the extension of indication for the use of the Spikevax vaccine (Modern) for the age group between 12 and 17 years, fully accepting the opinion expressed by the European Medicines Agency (EMA).
According to the CTS, in fact, the available data demonstrate the efficacy and safety of the vaccine even for subjects in this age group.
Article published on 28 July 2021 - 14:40